Biological medicines for asthma

RX_ASTMA_BIOL

No definition available.

Endpoint definition

↥
FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Medicine purchases: ATC R03DX05|R03DX08|R03DX09|R03DX10|D11AH05

1 out of 7 registries used, show all original rules.

180

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

180

diagram downward connector

Include endpoints None

180

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

175

diagram downward connector
RX_ASTMA_BIOL

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze DF5

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 175 105 70
Unadjusted prevalence (%) 0.05 0.05 0.04
Mean age at first event (years) 51.63 51.18 52.30

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: RX_ASTMA_BIOL – Biological medicines for asthma
GWS hits:

Survival analyses between endpoints

↥

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Biological medicines for asthma

↥

Endpoint not on priority list, no data to show.